Prescribed and Depleted: How Widely Used Medications May Be Quietly Compromising Your Cellular Energy Systems

A Hidden Variable in Chronic Disease Management

The United States has one of the highest rates of prescription drug use in the developed world. According to data from the Centers for Disease Control and Prevention, nearly half of all Americans have taken at least one prescription medication in the past 30 days, and roughly a quarter take three or more. For the millions managing conditions such as cardiovascular disease, type 2 diabetes, depression, or chronic pain, pharmaceutical intervention is not optional—it is frequently life-sustaining.

Yet the clinical conversation surrounding these medications rarely includes a discussion of their mitochondrial effects. The fatigue, cognitive fog, muscle weakness, and metabolic sluggishness that many patients attribute to their underlying conditions may, in some cases, be compounded—or even primarily caused—by the drugs prescribed to treat those conditions. Recognizing this distinction is not an argument against medication. It is an argument for metabolic completeness in medical care.

Statins: The CoQ10 Depletion Problem

Statins are among the most prescribed medications in the United States, with tens of millions of Americans taking drugs such as atorvastatin (Lipitor), rosuvastatin (Crestor), and simvastatin (Zocor) to manage elevated LDL cholesterol. Their primary mechanism—inhibition of the enzyme HMG-CoA reductase—is well understood. Less widely communicated is the fact that this same enzyme is required for the synthesis of coenzyme Q10 (CoQ10), a molecule that plays an indispensable role in mitochondrial electron transport.

CoQ10 functions as a mobile electron carrier within the inner mitochondrial membrane, shuttling electrons between complexes I and II to complex III. Without adequate CoQ10, the electron transport chain cannot operate efficiently, ATP production declines, and electron leak increases—generating excess reactive oxygen species that damage mitochondrial membranes and DNA.

A 2015 meta-analysis published in Nutrition reviewed 12 randomized controlled trials and confirmed that statin therapy consistently reduces circulating CoQ10 levels, with reductions ranging from 16 to 54 percent depending on drug, dose, and duration. The clinical manifestation most commonly associated with this depletion is statin-associated myopathy—muscle pain, weakness, and fatigue affecting an estimated 5 to 29 percent of statin users, depending on the diagnostic criteria applied.

For patients who experience these symptoms, supplemental CoQ10 at doses between 100 and 300 mg per day (preferably as ubiquinol, the reduced and more bioavailable form) has demonstrated benefit in several clinical trials, though the evidence base remains heterogeneous. Importantly, CoQ10 supplementation does not interfere with statin efficacy and carries a well-established safety profile.

Metformin: Mitochondrial Suppression as Both Mechanism and Side Effect

Metformin is the first-line pharmacological treatment for type 2 diabetes and is increasingly prescribed off-label for weight management and longevity purposes. Its glucose-lowering effects are partly mediated by inhibition of mitochondrial complex I in hepatic cells, which reduces ATP production, activates AMPK, and ultimately suppresses hepatic glucose output.

This mitochondrial inhibition is, paradoxically, both the drug's primary mechanism of therapeutic action and a source of potential systemic concern with long-term use. Complex I inhibition in non-hepatic tissues—including skeletal muscle and cardiac cells—may reduce overall aerobic capacity and contribute to the fatigue reported by a meaningful subset of metformin users.

Additionally, metformin impairs the absorption of vitamin B12 through a mechanism involving calcium-dependent membrane transport in the ileum. Long-term metformin use is associated with B12 deficiency in 10 to 30 percent of users, according to data published in Diabetes Care. Vitamin B12 is essential for the methylation cycle and for maintaining myelin integrity, and its depletion can produce neurological symptoms—peripheral neuropathy, cognitive impairment, and fatigue—that are frequently misattributed to diabetic progression rather than drug-induced nutrient loss.

Patients on long-term metformin should discuss routine B12 monitoring with their physician and consider supplementation with methylcobalamin, the neurologically active form, at doses of 500–1,000 mcg daily.

Antidepressants: Mitochondrial Effects Across Drug Classes

Selective serotonin reuptake inhibitors (SSRIs) such as sertraline (Zoloft) and fluoxetine (Prozac) are among the most prescribed medications in the United States. Their mitochondrial effects are less linear than those of statins or metformin but are increasingly documented in the research literature.

Several SSRIs and tricyclic antidepressants have been shown in preclinical and clinical studies to inhibit mitochondrial complex I and complex III activity, reduce membrane potential, and impair calcium homeostasis within the mitochondrial matrix. A 2019 review in Translational Psychiatry noted that mitochondrial dysfunction itself is implicated in the pathophysiology of major depressive disorder, creating a situation in which the treatment and the condition share overlapping cellular effects.

Carnitine depletion is an additional concern with certain antidepressant classes. L-carnitine is required to transport long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation—the primary fuel pathway during sustained low-intensity activity and fasting. Valproate, commonly prescribed for bipolar disorder and mood stabilization, is among the best-documented pharmacological depletors of carnitine, with plasma carnitine levels in long-term users sometimes falling well below clinical reference ranges.

Patients experiencing persistent fatigue on antidepressant or mood-stabilizing regimens may benefit from discussing carnitine status assessment with their provider. Supplemental L-carnitine or acetyl-L-carnitine (which additionally crosses the blood-brain barrier and supports cognitive function) at doses of 500–2,000 mg per day has been studied in this context with generally favorable tolerability.

Antibiotics: The Mitochondrial Ancestry Problem

Mitochondria are evolutionarily derived from ancient proteobacteria that formed an endosymbiotic relationship with early eukaryotic cells. This ancestry has a clinically significant consequence: certain antibiotic classes that target bacterial cellular machinery also affect mitochondrial function in human cells.

Fluoroquinolone antibiotics—ciprofloxacin (Cipro) and levofloxacin (Levaquin) among the most commonly prescribed—inhibit bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication. Mitochondrial DNA replication depends on structurally analogous enzymes, and fluoroquinolones have been shown in multiple studies to reduce mitochondrial DNA copy number, impair respiratory chain function, and increase oxidative stress in human cells.

This mechanism is believed to underlie the syndrome informally known as "fluoroquinolone toxicity" or "floxing"—a constellation of symptoms including tendinopathy, peripheral neuropathy, cognitive disturbance, and profound fatigue that can persist for months to years after drug discontinuation in susceptible individuals. The FDA has issued multiple safety communications regarding fluoroquinolone-associated disability, and current guidelines recommend reserving these drugs for infections where alternatives are unavailable.

Tetracyclines and macrolides, which target bacterial ribosomes, similarly affect mitochondrial ribosomes to a lesser but measurable degree, particularly with prolonged courses. Magnesium and antioxidant support (particularly with NAC or alpha-lipoic acid) during and after antibiotic therapy may help mitigate some of the oxidative burden imposed on mitochondria.

NSAIDs: Uncoupling and Membrane Disruption

Nonsteroidal anti-inflammatory drugs such as ibuprofen (Advil, Motrin) and naproxen (Aleve) are among the most frequently used over-the-counter medications in the United States, and prescription-strength formulations are widely prescribed for musculoskeletal and inflammatory conditions. Beyond their well-publicized gastrointestinal and cardiovascular risks, NSAIDs exert direct effects on mitochondrial function.

Several NSAIDs, including aspirin at high doses, act as mitochondrial uncouplers—dissipating the proton gradient across the inner mitochondrial membrane that drives ATP synthase. Uncoupling reduces ATP yield per unit of substrate oxidized and generates heat as a byproduct. Chronic NSAID use has also been associated with inhibition of mitochondrial complex I in hepatic and intestinal cells, contributing to the oxidative stress that partially explains their hepatotoxic potential at elevated doses.

Having the Conversation with Your Physician

None of the information presented here constitutes a recommendation to discontinue prescribed medications. For the vast majority of patients, the clinical benefit of these drugs substantially outweighs the mitochondrial costs described above—particularly when those costs can be meaningfully mitigated through targeted nutritional support.

The more productive clinical conversation centers on three questions: Is my current drug regimen being monitored for micronutrient depletion? Are any of my current symptoms potentially attributable to drug-induced mitochondrial impairment rather than disease progression? And are there evidence-based nutritional adjuncts that could support my cellular energy systems without interfering with my medication's efficacy?

Physicians who practice functional or integrative medicine are often more conversant with these questions than conventional practitioners, but any informed provider should be willing to engage with them. Requesting periodic assessment of CoQ10, B12, carnitine, and magnesium levels is a reasonable starting point for patients on long-term statin, metformin, antidepressant, or antibiotic therapy.

Supporting the System That Supports Everything Else

The mitochondria do not operate in isolation from the broader pharmaceutical and biochemical environment of the body. Every compound that enters circulation—whether therapeutic or nutritional—interacts with the cellular machinery that produces energy. Approaching prescription drug use with this awareness does not diminish the value of modern pharmacology. It elevates the standard of care by ensuring that the infrastructure of cellular energy is actively protected, not passively depleted, in the course of treating the conditions that depend on it.